DEA on ’08 PSE needs
This article was originally published in The Tan Sheet
The Drug Enforcement Agency seeks comments on its proposed revised assessment of 2008 annual U.S. needs of ephedrine, pseudoephedrine and phenylpropanolamine in a June 23 Federal Register notice. It will accept comments through July 23. DEA did not change the original projection assessment, with the proposed medical, scientific, research and production needs of ephedrine (for sale) estimated at 11,500 kg, pseudoephedrine (for sale) at 511,100 kg and phenylpropanolamine (for sale) at 5,545 kg. The projections are based on 2007 year-end inventory and disposition data from quota recipients. An interim final rule to apply the Combat Meth Act requires firms that use the substances to apply by each April 1 for the next year's manufacturing quotas ("1The Tan Sheet" July 16, 2007, p. 8)...
You may also be interested in...
Firms using ephedrine, pseudoephedrine, and phenylpropanolamine in drug products must apply by April 1 each year for the following year's manufacturing quotas, under a July 10 interim final rule to implement the Combat Meth Act
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.